Matrix metalloproteinase 9 and transglutaminase 2 expression at the ocular surface in patients with different forms of dry eye disease.

OBJECTIVE To evaluate the expression of matrix metalloproteinase 9 (MMP9) and transglutaminase 2 (TG2) in different forms of dry eye. DESIGN Case control study. PARTICIPANTS Seventy-five female subjects divided into 3 groups: group 1, 15 healthy controls; group 2, 30 subjects with Sjögren syndrome (SS); and group 3, 30 subjects with Meibomian gland dysfunction (MGD). METHODS A clinical assessment was carried out and impression cytologic specimens were processed for immunoperoxidase staining for MMP9 and TG2 and real-time polymerase chain reaction analyses were carried out for MMP9, TG2, interleukin-6, interferon-γ, B-cell lymphoma 2, and caspase 3. To study MMP9 and TG2 expression after anti-inflammatory treatment, patients were divided into 2 subgroups, one treated with saline and the other treated with saline plus topical corticosteroid eye drops (0.5% loteprednol etabonate) 4 times daily for 15 days. For statistical analysis, Student t test, Mann-Whitney U test, and Spearman's correlation coefficient were used as appropriate. MAIN OUTCOME MEASURES Conjunctival expression of MMP9 and TG2. RESULTS MMP9 and TG2 expression were higher in both patient groups than in controls (P < 0.0001). Group 2 patients showed higher expression than group 3 (P < 0.0001). The Spearman's correlation coefficient showed in group 2 a positive correlation between MMP9 and TG2 expression (ρ = 0.437; P = 0.01), but no correlation in group 3 (ρ = 0.143; P = 0.45). Corticosteroid treatment significantly reduced MMP9 and TG2 expression in both groups, ameliorating symptoms and signs. A much higher percentage reduction was observed in SS. CONCLUSIONS The pathogenic mechanisms of the 2 forms of dry eye give an account for the different MMP9 and TG2 expressions in the 2 groups of patients. The higher expression in SS is determined by the direct autoimmune insult to the ocular surface epithelia, whereas in MGD patients, with an epithelial damage due to an unbalanced tear secretion, the molecules expression is significantly lower, although higher than in controls. The corticosteroid treatment induced a reduction of both molecules, although higher in SS than in MGD, because of its direct inhibitory effect on inflammation.

[1]  I. Gipson,et al.  Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. , 2000, Archives of ophthalmology.

[2]  Lee Stern,et al.  Dysfunctional Tear Syndrome: A Delphi Approach to Treatment Recommendations , 2006, Cornea.

[3]  K. Tsubota,et al.  IL-6 induction in desiccated corneal epithelium in vitro and in vivo , 2011, Molecular vision.

[4]  D. Dartt,et al.  Modulation of Conjunctival Goblet Cell Function by Inflammatory Cytokines , 2013, Mediators of inflammation.

[5]  De-Quan Li,et al.  Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. , 2009, Investigative ophthalmology & visual science.

[6]  R. Jonsson,et al.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group , 2002, Annals of the rheumatic diseases.

[7]  P. Aragona,et al.  Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjögren's syndrome patients , 2002, The British journal of ophthalmology.

[8]  A. Roszkowska,et al.  Safety and Efficacy of 0.1% Clobetasone Butyrate Eyedrops in the Treatment of Dry Eye in Sjögren Syndrome , 2013, European journal of ophthalmology.

[9]  S. Yeo,et al.  Hyperosmolarity‐mediated mitochondrial dysfunction requires Transglutaminase‐2 in human Corneal epithelial cells , 2010, Journal of cellular physiology.

[10]  P. Aragona,et al.  Towards a dynamic customised therapy for ocular surface dysfunctions , 2013, British Journal of Ophthalmology.

[11]  De-Quan Li,et al.  IL-17 disrupts corneal barrier following desiccating stress , 2009, Mucosal Immunology.

[12]  N. Bodor,et al.  Metabolism, Distribution, and Transdermal Permeation of a Soft Corticosteroid, Loteprednol Etabonate , 1992, Pharmaceutical Research.

[13]  S. Yeh,et al.  Apoptosis of ocular surface cells in experimentally induced dry eye. , 2003, Investigative ophthalmology & visual science.

[14]  Murat Dogru,et al.  The international workshop on meibomian gland dysfunction: report of the clinical trials subcommittee. , 2011, Investigative ophthalmology & visual science.

[15]  L. Benjamin,et al.  Meibomian gland disease. Classification and grading of lid changes , 1991, Eye.

[16]  J. McCulley,et al.  Meibomian Gland Triglyceride Fatty Acid Differences in Chronic Blepharitis Patients , 1996, Cornea.

[17]  W. Mathers Meibomian gland disease , 2004 .

[18]  G. Li Volti,et al.  Effect of growth factors and steroids on transglutaminase activity and expression in primary astroglial cell cultures , 2008, Journal of neuroscience research.

[19]  J. Shoji,et al.  Regulation of soluble interleukin-6 (IL-6) receptor release from corneal epithelial cells and its role in the ocular surface , 2011, Japanese Journal of Ophthalmology.

[20]  A. Bron,et al.  Predicted phenotypes of dry eye: proposed consequences of its natural history. , 2009, The ocular surface.

[21]  D. Zoukhri Effect of inflammation on lacrimal gland function. , 2006, Experimental eye research.

[22]  A. Tomlinson,et al.  Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. , 2013, The ocular surface.

[23]  L. Fésüs,et al.  Transglutaminase 2 in the balance of cell death and survival , 2005, FEBS letters.

[24]  Marisa Meloni,et al.  Molecular mechanism of ocular surface damage: Application to an in vitro dry eye model on human corneal epithelium , 2011, Molecular vision.

[25]  H. Jun,et al.  Transglutaminase type 2 in human abdominal aortic aneurysm is a potential factor in the stabilization of extracellular matrix. , 2013, Journal of vascular surgery.

[26]  Jun Shimazaki,et al.  The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. , 2011, Investigative ophthalmology & visual science.

[27]  M. Fini,et al.  Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. , 2005, The American journal of pathology.

[28]  S. Pflugfelder,et al.  Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. , 1999, Ophthalmology.

[29]  De-Quan Li,et al.  Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. , 2006, Investigative ophthalmology & visual science.

[30]  A. Roszkowska,et al.  Effects of amino acids enriched tears substitutes on the cornea of patients with dysfunctional tear syndrome , 2013, Acta ophthalmologica.

[31]  S. Keshavjee,et al.  MMP9 modulates tight junction integrity and cell viability in human airway epithelia. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[32]  P. Aragona,et al.  Meibomian gland dysfunction and ocular discomfort in video display terminal workers , 2008, Eye.

[33]  K. Yoon,et al.  Hyperosmolarity-induced cornification of human corneal epithelial cells is regulated by JNK MAPK. , 2008, Investigative ophthalmology & visual science.

[34]  Heesang Song,et al.  Tissue transglutaminase 2 promotes apoptosis of rat neonatal cardiomyocytes under oxidative stress , 2011, Journal of receptor and signal transduction research.

[35]  R. Dana,et al.  The international workshop on meibomian gland dysfunction: report of the clinical trials subcommittee. , 2011, Investigative ophthalmology & visual science.

[36]  Gerd Geerling,et al.  Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[37]  M. Lemp Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. , 1995, The CLAO journal : official publication of the Contact Lens Association of Ophthalmologists, Inc.

[38]  De-Quan Li,et al.  Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. , 2006, Experimental eye research.

[39]  Wenshu Chen,et al.  Epidermal Growth Factor Receptor-mediated Tissue Transglutaminase Overexpression Couples Acquired Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance and Migration through c-FLIP and MMP-9 Proteins in Lung Cancer Cells* , 2011, The Journal of Biological Chemistry.

[40]  De-Quan Li,et al.  Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. , 2004, Investigative ophthalmology & visual science.

[41]  S. Kojima,et al.  Free fatty acids induce transglutaminase 2‐dependent apoptosis in hepatocytes via ER stress‐stimulated PERK pathways , 2012, Journal of cellular physiology.

[42]  B. Glasgow,et al.  The international workshop on meibomian gland dysfunction: report of the subcommittee on tear film lipids and lipid-protein interactions in health and disease. , 2011, Investigative ophthalmology & visual science.

[43]  J. Chodosh,et al.  A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. , 2004, American journal of ophthalmology.

[44]  M. Raghunath,et al.  Transglutaminase activity in the eye: cross-linking in epithelia and connective tissue structures. , 1999, Investigative ophthalmology & visual science.

[45]  R. Beuerman,et al.  Transglutaminase participates in UVB-induced cell death pathways in human corneal epithelial cells. , 2006, Investigative ophthalmology & visual science.

[46]  Yunhee Lee,et al.  Matrix Metalloproteinase Gelatinase B (MMP-9) Coordinates and Effects Epithelial Regeneration* , 2002, The Journal of Biological Chemistry.

[47]  M. Musumeci,et al.  Acidic Mammalian Chitinase in Dry Eye Conditions , 2009, Cornea.

[48]  P. Aragona,et al.  Comparison of ocular surface disease index and tear osmolarity as markers of ocular surface dysfunction in video terminal display workers. , 2014, American journal of ophthalmology.

[49]  L. Wheeler,et al.  Mitochondrial permeability transition pore in inflammatory apoptosis of human conjunctival epithelial cells and T cells: effect of cyclosporin A. , 2013, Investigative ophthalmology & visual science.

[50]  Maya Ram,et al.  Matrix Metalloproteinase-9 and Autoimmune Diseases , 2006, Journal of Clinical Immunology.

[51]  Christophe Baudouin,et al.  The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). , 2007, The ocular surface.

[52]  J. Mehta,et al.  Comparative analysis of two femtosecond LASIK platforms using iTRAQ quantitative proteomics. , 2014, Investigative ophthalmology & visual science.